Merck (MRK) Options Show Bullish Skew at $122–127 as M&A and Earnings Fuel Near-Term Optimism

• Current price: $121.33 (up 0.86%)
• Strong call skew on this Friday's options with heavy OI at $122–$127 calls
• Analyst upgrades and blockbuster drug progress add fuel to the fire
• Merck's recent $6.7B Terns acquisition shows strategic bullish momentum

There’s a clear story unfolding for Merck today. The stock is up nearly 0.9%, and the options market is echoing this bullish shift with heavy call interest at the $122 and $127 levels. This isn’t just a short-term pop—it’s a sign of growing confidence in Merck’s long-term momentum. The stock is sitting on top of strong technical indicators, and the options data suggests many traders are already positioning for a breakout.

What the Options Are Saying About Sentiment and Risk

Let’s start with the options. This Friday’s options chain shows a clear call skew, with 2,249 open interest at the $122 call and 727 at the $127 call. These are the two biggest call strikes on the board. That’s not just noise—it’s a signal. Traders are betting Merck will break through $122 and test the $127 level before the weekend.

On the put side, there’s also activity, but it’s more defensive. The $117 and $118 puts have the most open interest, totaling around 2,459 contracts. That means some traders are hedging below $120, but it’s not enough to tip the scale toward bearish sentiment.

The total put/open interest ratio is 0.705, which is a moderate call skew. That means more money is flowing into bullish positions than bearish ones right now. That kind of imbalance usually happens when the market is either reacting to news or building momentum ahead of a key catalyst—like a conference call or a major drug trial result.

There are no notable whale moves or block trades on the books today, so we can assume this is retail and institutional activity pushing the skew higher.

Merck’s M&A, Earnings, and Drug Progress Back the Bull Case

The bullish options action isn’t coming out of thin air. Merck’s recent acquisition of Terns Pharma for $6.7 billion isn’t just a headline—it’s a calculated move to strengthen its oncology pipeline. TERN-701, the lead drug from the deal, is showing strong activity in late-stage leukemia trials. That kind of progress doesn’t go unnoticed by the market.

On the earnings front, Merck just beat Q4 2025 estimates, and the company is guiding for continued growth in 2026. With a dividend yield of 2.8% and annualized yield of $3.40, Merck is a favorite among income-focused investors. That stability helps justify the bullish options activity—investors aren’t betting on a flash in the pan. They’re betting on a company with strong fundamentals, a robust R&D pipeline, and a history of consistent performance.

The upcoming April 30th earnings call is another catalyst on the calendar. Analysts expect Merck to provide further insight into its growth trajectory and the integration of Terns. If the company delivers strong guidance or hints at more M&A, the $127 call could become a magnet for capital.

Actionable Trades: Where to Play the Momentum

For traders, Merck offers a few clean setups:

1. Long Calls for the Near-Term Pop: With Merck at $121.33, the MRK20260403C122 call (expiring this Friday) looks like a high-conviction play. If Merck breaks above $122.50 (which it did intraday), this option could see significant gains. It’s a short-term bet that plays on the current momentum and the expected earnings call.

1. Straddle or Call Spread for the Next Week: For those who want to extend the timeline, the MRK20260410C127 call (expiring next Friday) is worth a look. With 1,022 open interest, it’s the most popular out-of-the-money call for the extended window. If Merck shows strength tomorrow and the bulls continue to build steam, this could be a strong entry point.

1. Stock Play: Test the $122.50 Level: For investors, Merck is in a short-term bullish trend with a strong RSI of 65.74 and a bullish MACD. The 30-day moving average is at 118.56, and the stock is well above it. A clean entry would be around $121.00–$121.50 with a stop just below the intraday low of $120.34. A target of $125–$127 is reasonable, based on both technical resistance and options positioning.

1. Puts for Cautious Long-Term Investors: If you like Merck’s story but want to hedge, the MRK20260403P118 put could serve as a downside anchor for next Friday. It’s got 1,106 OI and is a reasonable distance from the current price. It won’t save you if Merck tanks, but it will provide some peace of mind.

Bullish Trends Ahead: Merck Looks to Make a Move

Merck is at a turning point. With a growing pipeline, a strong balance sheet, and a bullish options setup, the stock is primed for a run. The key is to identify where the momentum is strongest and where the options market is already pricing in a move. The call skew at $122–$127 is telling us that traders are already seeing a path to $125 and beyond.

That doesn’t mean we ignore the risks. Merck isn’t immune to market-wide volatility or sector-specific headwinds. But for now, the data says: bull case is in control.

If you’re watching Merck this week, keep your eyes on $122.50 and $127. If those levels hold and show strength, Merck could be just getting started.

Now’s the time to lean in—whether with a stock position or a well-priced call—before the next big catalyst.